Stories

The IRE Resource Center is a major research library containing more than 27,000 investigative stories.

Most of our stories are not available for download but can be easily ordered by contacting the Resource Center directly at 573-882-3364 or rescntr@ire.org where a researcher can help you pinpoint what you need.

Search results for "Theranos" ...

  • Bad Blood: Secrets and Lies in a Silicon Valley Startup

    In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. A riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.
  • The Downfall of Theranos

    The Wall Street Journal saved patients from harm by revealing fraud at the heart of one of Silicon Valley’s hottest companies.
  • The Downfall of Theranos

    The Wall Street Journal saved patients from harm by revealing fraud at the heart of one of Silicon Valley’s hottest companies. Were it not for the Journal’s reporting in 2016, tens of thousands of patients would have been put at risk and a company built on fraudulent foundations would still be a Silicon Valley darling. Theranos, a $9 billion laboratory startup, had promised to revolutionize blood testing by drawing just a few drops of blood with a finger prick. It wasn’t close. A team of Journal reporters, in a committed and extensive investigation, exposed how its technology didn’t work, how the company tried to cover up its failures and how patients’ lives were turned upside down and their health jeopardized.
  • Testing Theranos

    Americans have been fascinated with successful entrepreneurs since the days of Horatio Alger. In recent years, Silicon Valley billionaires like Apple’s Steve Jobs, Google’s Larry Page and Sergey Brin and Facebook’s Mark Zuckerberg have become icons. Elizabeth Holmes looked to be next. Claiming she was transforming medicine with her blood-testing company, Theranos Inc., the 31-year-old Stanford University dropout became a celebrity. The New Yorker and Fortune published admiring profiles. Time named her one of the 100 Most Influential People in the World. Harvard’s medical school appointed her to its prestigious board of fellows. President Obama named her a U.S. ambassador for global entrepreneurship. Theranos became the nation’s largest private health-care startup, with Ms. Holmes’s stake valued at more than $4.5 billion.
  • Private Risk

    In a year-long series, The Wall Street Journal exposed and analyzed the underbelly of Silicon Valley’s technology boom with powerful reporting that triggered action by federal regulators, the nation’s largest drugstore chain and major retailers. Among the many highlights was an expose of blood-testing firm Theranos Inc., detailing how the nation’s largest private health-care company hit technological snags—with employees filing complaints with regulatory agencies alleging the company concealed problems—as it performed millions of blood tests on patients. The articles selected here—from dozens of stories, infographics and videos in the Journal’s “Private Risk” series—also revealed how technology firms fudge their finances; how private tech shares are improperly traded in a shadowy market; and how millions of American own shares of private tech firms through their mutual funds with no idea about what they’re actually worth.